Skip to main content

Advertisement

SpringerLink
Log in

No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

BRD7 (bromodomain 7), a subunit of poly-bromo-associated BRG1-associated factor (PBAF)-specific Swi/Snf chromatin remodeling complexes, has been proposed as a tumour suppressor protein following its identification as an important component of both functional p53 and BRCA1 (breast cancer 1, early onset) pathways. As low BRD7 expression levels have been linked to p53-wild-type breast tumour cells, we hypothesized an implication of BRD7 germline alterations in the pathogenesis of hereditary breast cancer similar to that of TP53 in Li-Fraumeni syndrome. We performed sequence analysis of the BRD7 gene on 61 high-risk individuals with hereditary or very-early-onset breast cancer and 100 healthy controls. Four potentially disease-causing single-nucleotide alterations were detected within the cohort of breast cancer patients (one listed as a rare single-nucleotide polymorphism (SNP) in the NCBI (National Center for Biotechnology Information) SNP database). Two of the detected variants were also each found once within the control collective. Segregation analysis on both families of those carrying the remaining two variants revealed segregation of these BRD7 alterations independent of breast cancer. In conclusion, it seems that the BRD7 variants we detected represent rare polymorphisms and mainly rule out BRD7 as a frequent high-penetrance breast cancer susceptibility gene. However, further analyses in larger cohorts of women with hereditary breast cancer should clarify the role of BRD7 in breast cancer predisposition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R, Del Sal G (2010) BRD7 is a candidate tumour suppressor gene required for p53 function. Nature Cell Biol 12:380–389

    Article  PubMed  CAS  Google Scholar 

  2. Harte MT, O’Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, Mullan PB, Harkin DP (2010) BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 70:2538–2547

    Article  PubMed  CAS  Google Scholar 

  3. Beroukhim R, Mermel CH, Porter D et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905

    Article  PubMed  CAS  Google Scholar 

  4. Burrows AE, Smogorzewska A, Elledge SJ (2010) Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci USA 107:14280–14285

    Article  PubMed  CAS  Google Scholar 

  5. Liu H, Zhang L, Niu Z, Zhou M, Peng C, Li X, Deng T, Shi L, Tan Y, Li G (2008) Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer 8:253

    Article  PubMed  CAS  Google Scholar 

  6. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71

    Article  PubMed  CAS  Google Scholar 

  7. Li FP, Fraumeni JF Jr (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752

    PubMed  CAS  Google Scholar 

  8. Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46:689–693

    Article  PubMed  CAS  Google Scholar 

  9. Lalloo F, Varley J, Ellis D, Moran A, O’Dair L, Pharoah P, Evans DG; Early Onset Breast Cancer Study Group (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101–1102

    Article  Google Scholar 

  10. Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563–567

    Article  PubMed  CAS  Google Scholar 

  11. Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347

    Article  PubMed  CAS  Google Scholar 

  12. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK (2011) Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 108:323–330

    PubMed  Google Scholar 

  13. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101–124

    PubMed  CAS  Google Scholar 

  14. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27:e108–e109

    Article  PubMed  Google Scholar 

  15. Antoniou AC, Beesley J, McGuffog L et al (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70:9742–9754

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge all women and their families for participating in this study, Friederike Grundstedt, Bernd Haermeyer, and Marcel Tauscher for their technical assistance in mutation analysis, and Gillian Teicke for her support in preparing the manuscript. This work was supported by the Hannover Biomedical Research School StrucMed doctorate program, GSC 108 (DFG – German Research Foundation).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Author notes

  1. Dorothea Gadzicki

    Present address: MVZ MediVision Altona, Lornsenstr. 6, 22767, Hamburg, Germany

Authors and Affiliations

  1. Institute of Cell and Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Judith Penkert, Brigitte Schlegelberger, Doris Steinemann & Dorothea Gadzicki

Authors
  1. Judith Penkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brigitte Schlegelberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Doris Steinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dorothea Gadzicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dorothea Gadzicki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penkert, J., Schlegelberger, B., Steinemann, D. et al. No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways. Familial Cancer 11, 601–606 (2012). https://doi.org/10.1007/s10689-012-9556-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-012-9556-0

Keywords

Search

Navigation